By: IPP Bureau
Last updated : August 19, 2026 6:16 pm
Operating revenue for the quarter grew a modest 3.93% year-on-year to Rs. 193.81 crore
Anuh Pharma Limited, a Mumbai-based active pharmaceutical ingredient (API) manufacturer, reported a quarter in which profit growth significantly outpaced revenue, as a shift toward higher-value products in regulated markets lifted margins across the board.
The company shared its Q1 FY 2026-27 investor presentation in a filing with BSE and NSE on August 19, 2026, under Regulation 30 of SEBI's listing disclosure norms.
Operating revenue for the quarter grew a modest 3.93% year-on-year to Rs. 193.81 crore. However, profitability metrics rose far more sharply: EBITDA jumped 41.56% to Rs. 19.36 crore, with margins expanding to 9.99% from 7.34% a year earlier.
Profit after tax grew 37.63% to Rs. 11.42 crore, while profit before tax rose 54.55% to Rs. 16.93 crore. Earnings per share came in at Rs. 1.14, up from Rs. 0.83 in the year-ago quarter.
Return on capital employed improved to 19.18%, up 326 basis points from the full-year FY26 figure of 15.92%. Production volumes rose 19.46% to 491 metric tonnes.
Joint Managing Directors Ritesh Shah and Vivek Shah attributed the outperformance to three factors: a richer product mix, disciplined cost control, and better throughput from existing assets.
They noted that with USFDA and EU GMP clearances now in place, the regulated-market pipeline has become the company's primary growth engine, with returns strengthening without added leverage.
Export revenue rose to roughly Rs. 88 crore from Rs. 70 crore a year earlier, even as the company's overall customer concentration eased — its top five customers accounted for 20% of sales in Q1 FY27, down sharply from 36% in the same quarter last year.
Within exports, Europe remained the largest geography at nearly 30% of export sales, followed by Asia at around 36% and Africa at roughly 28%.
Erythromycin remained the largest single product-revenue contributor, followed by higher macrolides and sulphadoxine, though several product lines saw year-on-year declines even as overall profitability improved.